FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies

Despite pre-clinical murine data supporting T regulatory (Treg) cell depletion as a major mechanism by which anti-CTLA-4 antibodies function in vivo, the two main antibodies tested in patients (ipilimumab and tremelimumab) have failed to demonstrate similar effects. We report analogous findings in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Knorr, David, Leidner, Rom, Jensen, Shawn, Meng, Ryan, Jones, Andrew, Ballesteros-Merino, Carmen, Bell, R. Bryan, Baez, Maria, Sprott, David, Bifulco, Carlo, Piening, Brian, Dahan, Rony, Fox, Bernard A., Ravetch, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884505/
https://www.ncbi.nlm.nih.gov/pubmed/36711504
http://dx.doi.org/10.1101/2023.01.19.522856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884505/
https://www.ncbi.nlm.nih.gov/pubmed/36711504
http://dx.doi.org/10.1101/2023.01.19.522856

Ejemplares similares